Recombinant human CD40/TNFRSF5 protein

CD40, also known as TNFRSF5, is a member of the TNF receptor superfamily. It transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglubiln secretion. CD40 is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. CD40 molecule is a potential target for cancer immunotherapy. There are number of completed and ongoing clinical trials where agonistic anti-CD40 monoclonal antibodies are employed to activate an anti-tumor T cell response via activation of dendritic cells. Recombinant human CD40, fused to hIgG-His-tag at C-terminus, was expressed in HEK293 cell and purified by using conventional chromatography techniques.

Product Specifications

Product Name Alternative

Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, p50, CD40L receptor, CDw40

Expression System

HEK293

Antigen Species

Human

Tag

HIgG-His-Tag

Applications

SDS-PAGE

Concentration

1 mg/mL (determined by Absorbance at 280 nm)

Endotoxin

< 1 EU per 1ug of protein (determined by LAL method)

Purity

> 95% by SDS - PAGE

Molecular Weight

46.1kDa (412aa)

Additionnal Information

ATGP4007-10 µg, ATGP4007-50 µg, ATGP4007-100 µg, ATGP4007-200ug, ATGP4007-250 µg, ATGP4007-500 µg, ATGP4007-1 mg, Bp50, CDW40, p50, TNFRSF5, tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, CD40L receptor, ATGP4007-10 µg, ATGP4007-20 µg, ATGP4007-50 µg, ATGP4007-100 µg, ATGP4007-250 µg, ATGP4007-500 µg, ATGP4007-1 mg, ATGP4007-10, ATGP4007-20, ATGP4007-50, ATGP4007-100, ATGP4007-250, ATGP4007-500, ATGP4007-1

References & Citations

Vonderheide RH, et al, (2013) Clin Cancer Res. 19:1035-1043.; ; Remer M., et al (2017) Curr Top Microbiol Immunol. 405:165-207.; ; Karnell JL, et al, (2019) Adv Drug Deliv Rev. 141:92-103.;